Ex vivo gene therapy and vision.

Area of Science:

• Ophthalmology
• Gene Therapy
• Neuroscience

Background:

• Blindness remains a significant global health issue, necessitating novel therapeutic strategies.
• Ex vivo gene therapy, involving cell manipulation outside the body, is emerging as a safe and targeted treatment approach.
• The visual system, including the eye and visual pathways, is a prime target for ex vivo gene therapy due to its specific anatomical structure.

Purpose of the Study:

• To review the latest advancements in ex vivo gene therapy for visual pathway disorders.
• To highlight the potential of ex vivo gene therapy in treating blindness and improving quality of life.
• To identify challenges hindering the clinical translation of ex vivo gene therapy for visual conditions.

Main Methods:

• Review of preclinical studies and research on ex vivo gene therapy applications in ophthalmology and neuroscience.
• Analysis of genetic reprogramming techniques for cell replacement and functional restoration.
• Examination of strategies for neuroprotection, inflammation modulation, and protein replacement in visual disorders.

Main Results:

• Ex vivo gene therapy has demonstrated significant progress in preclinical models for corneal diseases, glaucoma, retinal degeneration, stroke, and multiple sclerosis.
• Genetic reprogramming of cells is being utilized to replace damaged cells and restore function in the visual system.
• Advances include enhanced neuroprotection, modulation of inflammation, and replacement of deficient proteins relevant to visual health.

Conclusions:

• Ex vivo gene therapy presents a viable and advancing therapeutic avenue for a range of blindness-causing conditions.
• Further research and overcoming current challenges are crucial for the successful transition of ex vivo gene therapy into clinical practice for visual impairments.
• This approach holds substantial promise for improving patient outcomes and quality of life for individuals affected by visual pathway diseases.